Quackbusters Inc.: Hot On The Heels Of Medical Hucksters

Pseudomedicine Is A Multibillion Dollar Business In The U.S. On weekends, medical researcher Waflace I. Sampson often leaves his suburban home and drives up the peninsula into San. Francisco. He sees himself as an investigator "his quarry, an epidemic that’s ravaging the City by the Bay." But it’s not the AIDS virus he’s after. Although a hematologist by training, Sampson is hunting tainted medicine, not tainted blood He’s a quackbuster. In recent months, Sampson un

Written byRex Dalton
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Pseudomedicine Is A Multibillion Dollar Business In The U.S.
On weekends, medical researcher Waflace I. Sampson often leaves his suburban home and drives up the peninsula into San. Francisco. He sees himself as an investigator "his quarry, an epidemic that’s ravaging the City by the Bay." But it’s not the AIDS virus he’s after. Although a hematologist by training, Sampson is hunting tainted medicine, not tainted blood He’s a quackbuster.

In recent months, Sampson uncovered hucksters selling an unlicensed preparation allegedly containing interleukin2, an experimental drug not widely approved for clinical use against AIDS in the Battle Against Health Fraud United States. Sampson’s report contributed to the firm’s being put out of operation.

He also learned about "and issued a quack-alert concerning" a faith-healer he describes as "the Dallas Cowgirl cheerleader of AIDS patients." It seems this woman convinced AIDS sufferers that they can conquer the fatal disease simply by ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies